A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.

Qin, Shukui; Finn, Richard S.; Kudo, Masatoshi; Meyer, Tim; Vogel, Arndt; Ducreux, Michel; Mercade, Teresa Macarulla; Tomasello, Gianluca; Boisserie, Frederic; Hou, Jeannie; Li, Cindy; Song, James; Zhu, Andrew X.

doi:10.1200/JCO.2018.36.15_suppl.TPS3110

免费注册

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.

作者：Qin, Shukui; Finn, Richard S.; Kudo, Masatoshi; Meyer, Tim; Vogel, Arndt; Ducreux, Michel; Mercade, Teresa Macarulla; Tomasello, Gianluca; Boisserie, Frederic; Hou, Jeannie; Li, Cindy; Song, James; Zhu, Andrew X.

DOI：10.1200/JCO.2018.36.15_suppl.TPS3110

出版日期2018-5-20
单位中国人民解放军第八一医院

全文

访问全文

收藏分享被引(3) 浏览

更新时间：2021-07-02 06:16

相似论文
引用论文
参考文献

产品服务

科研之友科研之友机构版科创云

站内浏览

科研成果科研人员科研机构

服务支持

帮助中心隐私政策服务条款

联系方式

在线客服：【立即咨询】客户热线：400-1616-289 电子邮箱：support@scholarmate.com

微信公众号